BioPeptics
Reta - 30 mg (Triple Agonist Peptide)
Reta - 30 mg (Triple Agonist Peptide)
Couldn't load pickup availability
Retatrutide is a next-generation multi-receptor agonist peptide that simultaneously activates GLP-1 (Glucagon-Like Peptide-1), GIP (Glucose-Dependent Insulinotropic Polypeptide), and Glucagon receptors. This triple-agonist mechanism represents the most advanced approach in metabolic research to date - targeting weight regulation, glycaemic balance, lipid metabolism, and cellular energy optimization.
The Biopeptics Retatrutide 30 mg vial is supplied in lyophilized form to preserve potency, stability, and purity for laboratory and research settings.
For research use only.
How It Works
How It Works
1. GLP-1 Receptor Activation -Appetite & Glucose Control
Retatrutide mimics native GLP-1, enhancing insulin secretion while inhibiting glucagon release during high-glucose states. It also:
- Delays gastric emptying, extending satiety.
- Reduces appetite signals via hypothalamic pathways.
- Improves insulin sensitivity and β-cell survival.
- Decreases post-prandial glucose spikes and cravings.
These effects contribute to controlled food intake and improved metabolic efficiency in research models.
2. GIP Receptor Activation -Insulin & Adipose Metabolism
Activation of GIP receptors supports balanced insulin response and lipid utilization. GIP signaling has been shown to:
- Enhance insulin sensitivity in adipose tissue.
- Promote fat oxidation and energy expenditure.
- Reduce inflammation in metabolic tissues.
- Support stable glucose uptake across muscle and liver cells.
The dual GLP-1 + GIP stimulation creates a synergistic metabolic response, leading to improved glycaemic regulation in research applications.
3. Glucagon Receptor Activation -Fat Mobilization & Energy Turnover
Unlike single- or dual-agonists, Retatrutide also partially stimulates the glucagon receptor, which helps:
- Enhance basal metabolic rate (BMR).
- Promote lipolysis (fat-cell energy release).
- Increase mitochondrial biogenesis and oxygen consumption.
- Maintain lean-mass preservation during caloric restriction.
This triple-action results in a balanced metabolic shift toward fat utilization without compromising muscle mass.
Research Applications
Research Applications
- Glucose- and insulin-homeostasis research
- Obesity and metabolic-disorder models
- Studies in lipid metabolism and energy expenditure
- Investigation of receptor cross-signaling (GLP-1/GIP/Glucagon)
- Potential exploration in hepatic-fat-reduction and cardiometabolic health
Composition
Composition
Retatrutide -30 mg Lyophilized Peptide Powder
Dosage Guidance
Dosage Guidance
(Triple GLP-1 / GIP / Glucagon Receptor Agonist for Metabolic & Weight-Loss Research)
Reconstitution (Mixing)
- Add 3 ml Bacteriostatic Water to the vial.
- Roll gently between your palms (do not shake).
- Store in the refrigerator after mixing.
Concentration Calculation
30 mg ÷ 3 ml = 10 mg per ml
Every 10 units (0.1 ml) = 1 mg Retatrutide
Dosage Guidelines
For metabolic enhancement, glucose regulation, and fat-reduction research:
- Start: 1 mg (10 units) once per week to assess tolerance
-
Titration:
- Weeks 3–4 → 2 mg (20 units) weekly
- Weeks 5–6 → 4 mg (40 units) weekly
- Weeks 7+ → 6 mg (60 units) weekly or as tolerated
- Administration: Subcutaneous injection (abdomen, thigh, or upper arm)
- Frequency: Once weekly on the same day each week
Biopeptics recommendation:
Always start by assessing tolerance with a micro-dose of 1 mg, and stay on the lowest effective dose for as long as possible. Some individuals may not need to increase their dosage at all - only adjust the dose if truly necessary, and do so in very small increments.
Key Benefits:
- Potent triple-pathway action on GLP-1 / GIP / Glucagon receptors
- Enhances energy expenditure, fat oxidation, and metabolic flexibility
- Improves appetite control and glucose homeostasis
- Supports cardiovascular health and lean-mass preservation
Syringe Measurement Guide
|
Dose |
Volume (ml) |
Insulin Units (U-100 Syringe) |
|
1 mg |
0.10 ml |
10 units |
|
2 mg |
0.20 ml |
20 units |
|
4 mg |
0.40 ml |
40 units |
|
6 mg |
0.60 ml |
60 units |
Each 10 units (0.1 ml) = 1 mg Retatrutide.
Cycle Duration
Typical cycle: 12 – 24 weeks, depending on research goals.
Maintenance: Continue weekly dosing at the lowest effective level for ongoing metabolic support.
Important Notes
- Always use sterile needles and alcohol swabs.
- Do not reuse or share needles.
- Store reconstituted vial in the refrigerator (2 – 8 °C).
- For research use only.
- Possible transient effects: mild nausea, headache, fatigue, or injection-site redness.
Possible Side Effects (Observed in Research & Clinical Settings)
Possible Side Effects (Observed in Research & Clinical Settings)
Who Should Use with Caution / Avoid in Research Contexts
Who Should Use with Caution / Avoid in Research Contexts
- Personal or family history of medullary thyroid carcinoma (MTC) or MEN-2 (Multiple Endocrine Neoplasia type 2) -contraindicated in GLP-1–related research.
- Previous pancreatitis -monitor amylase/lipase markers if applicable.
- Gallbladder disease or gallstones -may increase biliary stasis risk.
- Severe GI motility disorders (gastroparesis).
- Pregnancy or breastfeeding -no safety data.
- Uncontrolled cardiovascular disease or arrhythmias -glucagon activity may raise heart rate.
- Concurrent insulin or sulfonylurea models -monitor for hypoglycemia.
Summary
Summary
Retatrutide represents the next generation of incretin-based metabolic peptides, offering enhanced fat oxidation, appetite control, and glucose balance in research models. Most side effects mirror those seen with GLP-1 analogs - GI upset, fatigue, or mild heart-rate increase -and are transient, dose-related, and self-limiting. Hydration, gradual titration, and proper dilution reduce discomfort and improve tolerance in controlled studies.
